CG Oncology (CGON) Expected to Announce Earnings on Tuesday

CG Oncology (NASDAQ:CGON) will likely be announcing its earnings results before the market opens on Tuesday, March 25th. Analysts expect the company to announce earnings of ($0.37) per share and revenue of $0.11 million for the quarter.

CG Oncology Stock Performance

Shares of CGON stock opened at $27.05 on Friday. CG Oncology has a twelve month low of $23.91 and a twelve month high of $46.99. The stock’s fifty day simple moving average is $28.08 and its 200 day simple moving average is $32.18.

Insider Activity at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 1,000 shares of the company’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $29.66, for a total transaction of $29,660.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Analysts Set New Price Targets

CGON has been the topic of a number of research reports. Royal Bank of Canada reissued an “outperform” rating and set a $66.00 target price on shares of CG Oncology in a report on Friday, December 6th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of CG Oncology in a report on Friday, January 10th. TD Cowen initiated coverage on CG Oncology in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Finally, Morgan Stanley reiterated an “overweight” rating and issued a $55.00 target price on shares of CG Oncology in a report on Friday, March 7th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $63.88.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.